Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Green, B. D
Right arrow Articles by Flatt, P. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes

Brian D Green

School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern Ireland, b.green{at}ulster.ac.uk

Nigel Irwin

Victor A Gault

Finbarr Pm O'Harte

Peter R Flatt

The rising prevalence of type 2 diabetes and increasing burden of diabetic complications requires new approaches to diabetes therapy. An encouraging new approach for development of future anti-diabetic drugs is based on analogues of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both peptides reduce postprandial glucose by stimulating glucose-dependent insulin release and exert a number of other beneficial actions including trophic effects on the beta-cell. Efforts are currently focused on developing stable analogues of GLP-1 and GIP which are resistant to dipeptidylpeptidase IV mediated degradation and renal filtration. Thus, by increasing the half-life and potency of these incretins, they should become a new class of agents for the treatment of type 2 diabetes.

Key Words: GLP-1 • GIP • incretin hormones • diabetes.

References

  • Unger RH, Eisentraut AM Entero-insular axis. Arch Int Med 1969;123: 261-6.[Abstract/Free Full Text]
  • Knowler WC, Pettitt DJ, Saad MF et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nut 1991;53: 1543S-51S.[Medline] [Order article via Infotrieve]
  • Ohneda M., Inman LR, Unger RH Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia 1995;38:173-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Inzucchi SE Oral antihperglycaemic therapy for type 2 diabetes. JAMA 2002;287:360-72.[Abstract/Free Full Text]
  • Krentz AJ, Bailey CJ Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003;308:207-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Göke R., Wagner B., Fehmann HC, Goke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med 1993;193:97-103.[Medline] [Order article via Infotrieve]
  • Green BD, Gault VA, O'Harte FPM, Flatt PR Structurally modified analogues of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) as future antidiabetic agents. Curr Pharm Des 2004;10:3651-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Farilla L., Bulotta A., Hirshberg B. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Turton MD, O'Shea D., Gunn et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kindmark H., Pigon J., Efendic S. Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab 2001;86:2015-19.[Abstract/Free Full Text]
  • Rudovich NN, Rochlitz HJ, Pfeiffer AF Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant firstdegree relatives of type 2 diabetic patients. Diabetes 2004;53:2359-65.[Abstract/Free Full Text]
  • Groop PH, Groop L., Totterman KJ, Fyhrquist F. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinol 1986;112:361-6.[Medline] [Order article via Infotrieve]
  • Meier JJ, Goetze O., Anstipp J. et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004;286:E621-E625.[Abstract/Free Full Text]
  • Meier JJ, Gallwitz B., Siepmann N. et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barrett AJ, Rawlings ND Oligopeptidases, and the emergence of the prolyl oligopeptidase family. Biol Chem 1992;373:353-60.[Web of Science]
  • Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gault VA, Parker JC, Harriott P., Flatt PR, O'Harte FPM. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002;175:525-33.[Abstract]
  • Meier JJ, Nauck MA, Kranz D. et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654-62.[Abstract/Free Full Text]
  • Gappa H., Baudys M., Koh JJ, Kim SW, Bae YH The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets. Tissue Eng 2001;7:35-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gutniak MK, Larsson H., Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 1996;19:843-8.[Abstract]
  • Burcelin R., Rolland E., Dolci W., Germain S., Carrel V., Thorens B. Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N Y Acad Sci 1999;875:277-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • O'Harte FPM, Gault VA, Parker JC et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 2002;45:1281-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gault VA, Flatt PR, Bailey CJ et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J 2002;367:913-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Green BD, Gault VA, Flatt PR, Harriott P., Greer B., O'Harte FPM. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion and in vivo antidiabetic actions following substitution of Ala8/Ala2 for 2-aminobutyric acid. Arch Biochem Biophys 2004;428: 136-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Holz GG, Chepurny OG Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003;10:2471-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kapitza C., Trautmann ME, Heise T., Heinemann L., Patterson, B. Daily Administration of LY307161 SR (GLP-1 Analog) Normalizes Blood Glucose in Type 2 Diabetes. Diabetes ADA Meeting San Francisco 2002; 341-OR.
  • Giannoukakis N. CJC-1131. ConjuChem. Curr Opin Investig Drugs 2003; 4:1245-9.[Medline] [Order article via Infotrieve]
  • Mark M. NN-2211. Novo Nordisk. IDrugs 2003;6:251-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Kreymann B., Williams G., Ghatei, MA, Bloom, SR Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-04.[Web of Science][Medline] [Order article via Infotrieve]
  • Meier JJ, Nauck MA, Siepmann N. et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003;52:1579-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nauck MA, El-Ouaghlidi A., Gabrys B. et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004;122:209-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kjems LL, Holst JJ, Volund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003;52:380-6.[Abstract/Free Full Text]
  • Meier JJ, Gallwitz B., Kask B. et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004;53:S220-S224.[Medline] [Order article via Infotrieve]
  • Lindsay JR, Au STB, Kelly CMN, O'Harte FPM, Flatt PR A novel aminoterminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with a prolonged insulinotropic activity in type 2 diabetes mellitus. Diabetes 2002;5:1394.
  • Balkan B., Kwasnik L., Miserendino R., Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999;42:1324-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ahren B., Holst JJ, Martensson H., Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000;404:239-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Deacon CF, Wamberg S., Bie P., Hughes TE, Holst JJ Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002;172:355-62.[Abstract]
  • Ahren B., Simonsson E., Larsson H. et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75.[Abstract/Free Full Text]
  • Mentlein R. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin Investig Drugs 2005;14:57-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Flatt PR, Bailey CJ, Kwasowski P., Swanston-Flatt SK, Marks V. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 1983;32:433-5.[Abstract]
  • Bailey CJ, Flatt PR, Kwasowski P., Powell CJ, Marks V. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol 1986;112:224-9.[Medline] [Order article via Infotrieve]
  • Miyawaki K., Yamada Y., Ban N. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 3, 134-140 (2005)
DOI: 10.1177/14746514050050030401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes and Vascular Disease ResearchHome page
Early and intensive treatment: glycaemic control in type 2 diabetes
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 145 - 146.
[PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
B. D Green, P. R Flatt, and C. J Bailey
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 159 - 165.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Green, B. D
Right arrow Articles by Flatt, P. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?